Argenx’s I.V. Vyvgart May See Continued Role In ITP, Despite SubQ Version Coming
Executive Summary
The company presented Phase III data for the I.V. formulation at ASH showing a high response rate in pretreated patients, a difficult-to-treat population. It also has a subcutaneous version in Phase III.
You may also be interested in...
Europe Biotech Heavyweights Genmab And Argenx Ink Antibody Alliance
The two flagship firms of the European biotech scene are pooling their technologies to jointly discover, develop and commercialize drugs against cancer and autoimmune diseases.
Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug
With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.
Launch Of Vyvgart Exceeds Argenx’s Expectations
Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.